Biotech News Alert: GenSpera (OTCQB:GNSZ) to Present Lead Drug Candidate Mipsagargin at 2nd Global Life Sciences Conference in Warsaw, Poland
Biotech News Alert: GenSpera (OTCQB: GNSZ) to Present Lead Drug Candidate Mipsagargin at 2nd Global Life Sciences Conference in Warsaw, Poland
SAN ANTONIO - September 30, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces Craig Dionne, PhD, GenSpera's CEO, will be presenting at the upcoming 2nd Global Life Sciences Conference on October 2, 2014, in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange.
The conference is sponsored by WedBush Europe and WDM Capital. Some of the Central and Eastern European leading life science institutional investors, fund managers and analysts will gather in Warsaw to discuss and assess new investment opportunities. More info: http://lscwarsaw.com.
Dr. Dionne will be giving a corporate presentation of the company's lead drug candidate, mipsagargin (G-202), currently in Phase II clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma (brain cancer).
A copy of the presentation will be made available on the Company's website, following the conference.
GenSpera has recently announced several key milestones and more information can be found by reviewing the press releases on the company's website http://www.genspera.com.
*United States Patent and Trademark Office (USPTO) issuance of patents US 8,822,406
"Tumor Activated Prodrugs" and US 8,772,226 B2 "Methods and compositions for the detection of cancer"
*Generic name "mipsagargin" for lead drug candidate G-202 per recommendation by World Health Organization's (WHO) International Nonproprietary Name (INN) group
*GenSpera Wins Summary Judgment in Mhaka Litigation
Read this release in full at http://www.investorideas.com/CO/GNSZ/news/2014/09301.asp
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.
For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.
Watch the Corporate Video: http://youtu.be/jULjEul-mBk
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Craig Dionne, PhD, CEO
Capital Markets Group
Media: Dawn Van Zant
Visit this company: www.genspera.com
More info on GNSZ at Investorideas.com Visit: http://www.investorideas.com/CO/GNSZ/
Disclaimer/Disclosure:Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.